Compare Cintas Corporation (CTAS) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Davita Inc — how do they compare? Cintas Corporation trades at $200.75 (market cap $78.78B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Cintas Corporation is far larger — about 7× Davita Inc's market cap, and Cintas Corporation pays a 1.05% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Davita Inc for 113 Days on average.
| CTAS | DVA | |
|---|---|---|
Market Cap | $78.78B | $11.28B |
Volume | 1,620,783 | 650,294 |
Sector | Industrials | Health |
52-Week High | $216.53 | $240.96 |
52-Week Low | $163.55 | $103.87 |
Typical Hold Time | 124 Days | 113 Days |
Enterprise Value | $81.25B | $24.00B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal and strong fundamental performance. Recent Q1 2027 earnings beat expectations with revenue of $3.01 billion and EPS of $1.39, driven by organic growth and margin expansion. The company raised fiscal 2027 guidance, reflecting confidence in continued momentum. Valuation multiples remain elevated with a P/E of 38.89, supported by robust profitability metrics including a 17.82% net income margin and 42.08% ROE.
The outlook for CTAS is positive, with earnings growth and raised guidance serving as key catalysts for potential upside toward the consensus price target of $234.60. Risks include high valuation sensitivity to growth sustainability and competitive pressures in the uniform rental sector. Analyst sentiment is moderately bullish, with 40% buy ratings, but investors should monitor execution against elevated expectations.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
